Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) trial - E4599

被引：2
|
作者：
Sandler, AB
Gray, R
Brahmer, J
Dowlati, A
Schiller, JH
Perry, MC
Johnson, DH
机构：
[1] Vanderbilt Ingram Canc Ctr, Nashville, TN USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Johns Hopkins Univ, Baltimore, MD USA
[4] Case Western Reserve Univ, Cleveland, OH 44106 USA
[5] Univ Wisconsin, Madison, WI USA
[6] Univ Missouri, Ellis Fischel Canc Ctr, Columbia, MO USA
来源：
LUNG CANCER | 2005年 / 49卷
关键词：
D O I：
10.1016/S0169-5002(05)80220-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S31 / S31
页数：1
相关论文
共 50 条
  • [31] Randomized phase II study comparing cisplatin plus pemetrexed plus bevacizumab with carboplatin plus paclitaxel plus bevacizumab in treatment-naive advanced non-squamous non-small cell lung cancer (CLEAR study)
    Koyama, R.
    Udagawa, H.
    Sugiyama, E.
    Komuta, K.
    Mori, M.
    Yokoyama, T.
    Sasaki, T.
    Saito, H.
    Ishida, H.
    Nakagawa, H.
    Sekine, A.
    Tamura, A.
    Shingyoji, M.
    Mizuno, K.
    Nakamura, A.
    Kinoshita, A.
    Yamanaka, T.
    Goto, K.
    ANNALS OF ONCOLOGY, 2018, 29
  • [32] Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: A phase II trial
    Johnson, DH
    Paul, DM
    Hande, KR
    Shyr, Y
    Blanke, C
    Murphy, B
    Lewis, M
    DeVore, RF
    JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (07) : 2054 - 2060
  • [33] Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: A phase III randomized trial
    Kosmidis, P
    Mylonakis, N
    Nicolaides, C
    Kalophonos, C
    Samantas, E
    Boukovinas, J
    Fountzilas, G
    Skarlos, D
    Economopoulos, T
    Tsavdaridis, D
    Papakostas, P
    Bacoyiannis, C
    Dimopoulos, M
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (17) : 3578 - 3585
  • [34] PHASE II STUDY OF INTERMITTENT ERLOTINIB (E) PLUS CARBOPLATIN (C), PACLITAXEL (P) AND BEVACIZUMAB (B) AS FRONTLINE TREATMENT OF PATIENTS (PTS) WITH ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSNSCLC): AVAFAST STUDY
    Cobo Dols, Manuel A.
    Blanco, Esperanza
    Bernabe, Reyes
    Fernandez, Inmaculada
    Inoriza, Angel
    Laura Ortega, Ana
    Valdivia, Javier
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1213 - S1213
  • [35] Randomized phase II trial of the biweekly schedule of adjuvant chemotherapy with carboplatin plus paclitaxel versus carboplatin plus gemcitabine in patients with non-small cell lung cancer (NSCLC)
    Sugio, K.
    Nagashima, A.
    Nakanishi, R.
    Uchiyama, A.
    Inoue, M.
    Osaki, T.
    Yoshimatsu, T.
    Takenoyama, M.
    Hanagiri, T.
    Yasumoto, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [36] Phase II trial of ixabepilone and carboplatin with or without bevacizumab in patients with previously untreated advanced non-small cell lung cancer
    Shipley, D.
    Spigel, D. R.
    Burris, H. A., III
    Waterhouse, D. M.
    Webb, C. D.
    Gian, V.
    Hart, L. L.
    Greco, F. A.
    Hainsworth, J. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [37] Toxicity analysis of SWOG 9509: A randomized phase III trial of paclitaxel plus carboplatin (PC) versus vinorelbine plus cisplatin (VC) in untreated patients with advanced non-small cell lung cancer (NSCLC). A Southwest Oncology Group Trial
    Kelly, K
    Crowley, J
    Bunn, PA
    Livingston, RB
    Gandara, DR
    SEMINARS IN ONCOLOGY, 1999, 26 (06) : 24 - 24
  • [38] Randomized phase III trial of nivolumab in combination with carboplatin, paclitaxel, and bevacizumab as first-line treatment for patients with advanced or recurrent non-squamous NSCLC
    Lee, J-S.
    Sugawara, S.
    Kang, J. H.
    Kim, H. R.
    Inui, N.
    Hida, T.
    Lee, K. H.
    Yoshida, T.
    Tanaka, H.
    Yang, C. T.
    Nishio, M.
    Ohe, Y.
    Tamura, T.
    Yamamoto, N.
    Yu, C-J.
    Akamatsu, H.
    Namba, Y.
    Sumiyoshi, N.
    Nakagawa, K.
    ANNALS OF ONCOLOGY, 2020, 31 : S1184 - S1185
  • [39] Phase III randomized trial comparing weekly vs. standard schedules of paclitaxel (P) plus carboplatin (C) for advanced non-small cell lung cancer (NSCLC): Analyses of elderly patients
    Belani, C
    Ramalingam, S
    Perry, M
    LaRocca, R
    Rinaldi, D
    Gable, P
    Tester, W
    LUNG CANCER, 2005, 49 : S32 - S32
  • [40] Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 as first line treatment of advanced non-small cell lung cancer (NSCLC)
    Hirsh, V.
    Boyer, M.
    Rosell, R.
    Benner, R. J.
    Readett, D.
    Schiller, J. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345